Becton, Dickinson and Company (NYSE:BDX) Traded Higher Than Its 50 Day Average


Company shares are trading at $211.03 a bit higher than $198.63, the stock’s 50 day moving average and which is marginally higher than the 200 day moving average of $194.17. The 50 day moving average moved up $12.40 and the 200 day average moved up $16.86. Trading volume for Becton, Dickinson and Company was 1,250K by the end of trading on Tuesday. Volume was up 34.17% over the stocks average daily volume.

Investors are more bearish on Becton, Dickinson and Company if you take into consideration the change in short interest. The company saw a rise in short interest of 2.04% between September 15, 2017 and September 29, 2017. Short shares grew 265,523 over that timeframe. With short interest at 13,275,910 and short average daily volume at 1,080,623, days to cover is 12.0 and the percentage of shorted shares was 0.06% on September 29.

Becton, Dickinson and Company (NYSE:BDX) has been the object of insider selling activity recently. Stephen Sichak, EVP disclosed the sale of 11,787 shares of BDX stock. The shares were purchased at an average price of $200.46. Sichak now owns $1,594,258 of the stock according to the SEC filing. EVP James C. Lim let go of 3,500 shares at an average price of $204.06 on Fri the 8th. Lim now owns $2,884,388 of stock as recorded in a recent Form 4 SEC filing.

EVP Linda M. Tharby sold 4,695 shares at an average price of $200.48 on August 22nd. That brings Tharby’s holdings to $2,272,842 per an SEC filing yesterday.

The following firms have recently changed their position in BDX. Mycio Wealth Partners, LLC grew its position by buying 350 shares an increase of 33.5% in the quarter. Mycio Wealth Partners, LLC now holds 1,395 shares valued at $273,000. The total value of its holdings increased 33.8%. As of quarter end Foothills Asset Management, Ltd. had sold 67 shares trimming its position 0.5%. The value of the investment in BDX decreased from $2,425,000 to $2,423,000 decreasing 0.1% quarter over quarter.

As of the end of the quarter Pineno Levin & Ford Asset Management, Inc. had acquired a total of 514 shares growing its stake by 1.9%. The value of the company’s investment in Becton, Dickinson and Company went from $5,280,000 to $5,403,000 a change of 2.3% for the reporting period. Robeco Institutional Asset Management B.v. cut its investment by shedding 67,705 shares a decrease of 30.3% from 06/30/2017 to 09/30/2017. Robeco Institutional Asset Management B.v. currently owns 155,725 shares with a value of $30,513,000. The value of the position overall is down by 30.0%.

August 10 investment analysts at Barclays maintained a stock rating of “Equal-Weight” and raised the price target to $210.00 from $158.00. Equity analyst Wells Fargo added BDX to its research portfolio giving it an initial rating of “Outperform”.

The company is down by 0.38% percent from yesterday’s close. The company also announced a dividend that was paid on Friday September 29th, 2017. The dividend payment was $0.730 per share for the quarter or $2.92 on an annualized basis. This dividend represents a yield of $1.38. The ex-dividend date was set for Thursday the 7th of September 2017.

The company’s P/E ratio is 61.11 and the market cap of the company is 48.02B. As of the latest earnings report the EPS was $3.45 and is expected to be $9.46 for the current year with 227,564,000 shares outstanding. Analysts expect next quarter’s EPS will be $2.45 and the next full year EPS is anticipated to be $10.41.

Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Company caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Business’s subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A..